PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

So thorough has been pop culture's assault on the English language that even the high priests of diction have ceded the inner sanctum. Among the words recently ushered into the august Oxford English ...

The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...

DENVER — Imagine a prescription drug that makes you gamble, have sex, overeat or go binge shopping. Abilify has been blamed for all of it. It’s one of the most profitable drugs in America. It’s why ...

Abilify (aripiprazole) is a prescription drug used to treat schizophrenia and other mental health conditions. Abilify comes as a tablet that you swallow. Abilify contains the active ingredient ...

Abilify (aripiprazole) is a prescription atypical (second-generation) antipsychotic that treats depression, schizophrenia, and bipolar disorder. It also treats irritability related to autism and ...

Settlement Approval Hearings Scheduled in Ontario and Québec for December 20, 2024 and January 8, 2025 and Certification of Ontario Action This notice was approved by the Ontario Superior Court of ...

MANHATTAN (CN) — Bristol-Myers Squibb reached a $19.5 million settlement Thursday on its off-label promotion of Abilify, an anti-psychotic that was originally designed to treat schizophrenia. Among ...

Dosage for Abilify (aripiprazole) may vary based on the condition it’s being used to treat. Your doctor may adjust your dosing of Abilify over the course of your treatment. The active ingredient in ...

PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...